Physician profile
Arjan Gower
NPI 1083106637
$4,025.10
in general payments reported to CMS, 2019-2025
14 companies · $3,054 in 2025
The $3,054 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.18 · 2020: $24.36 · 2021: $241 · 2022: $206 · 2023: $161 · 2024: $300 · 2025: $3,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,850 · Food and Beverage: $633 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,850.00 |
| Food and Beverage | $633.19 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,963.14 | 2023-2025 | |
| Genzyme Corporation | $183.67 | 2024 | |
| Beone Medicines USA, INC. | $152.97 | 2025 | Brukinsa |
| Incyte Corporation | $123.45 | 2021 | |
| Seagen INC. | $121.12 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $117.32 | 2021 | |
| Novo Nordisk INC | $85.81 | 2019-2023 | Wegovy |
| Secura Bio, INC. | $85.21 | 2022 | |
| Genentech USA, INC. | $58.44 | 2024-2025 | Tecentriq |
| Janssen Biotech, INC. | $30.70 | 2024 | Darzalex, Tecvayli, Talvey |
| Catalyst Pharmaceuticals, INC. | $30.61 | 2024 | |
| Alexion Pharmaceuticals, INC. | $25.44 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $24.36 | 2020 | |
| Array Biopharma INC | $22.86 | 2025 | Lorbrena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjan Gower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.